The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma

被引:18
作者
Wusiman, Dilinaer [1 ]
Guo, Lei [2 ]
Huang, Zehao [1 ]
Li, Zhengjiang [1 ]
Liu, Shaoyan [1 ]
Ying, Jianming [2 ]
Li, Wenbin [2 ]
An, Changming [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Head & Neck Surg, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Pathol, Beijing, Peoples R China
关键词
Head and neck squamous cell carcinoma; (HNSCC); Programmed death-ligand 1(PD-L1); Combined positive score (CPS); Type II diabetes; Overall survival; TUMOR-INFILTRATING LYMPHOCYTES; BODY-MASS INDEX; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS; CANCER; PD-1/PD-L1; CHEMOTHERAPY; ASSOCIATION; PREDICTS; IMMUNOTHERAPY;
D O I
10.1016/j.prp.2022.153934
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The expression of programmed cell death-ligand 1 (PD-L1) is being used as a predictive biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Our study was a retrospective cohort that assessed PD-L1 expression levels through immunohistochemistry (IHC) in 119 surgical specimens from HNSCC patients. The expression of PD-L1 was evaluated by IHC staining using the monoclonal antibody 22C3 (Dako) and the combined positive score (CPS). The relationship between the PD-L1 expression and clinicopathologic features was analyzed. 107 cases (89.9%) and 52 cases (43.7%) were positive for PD-L1 expression when the CPS cutoff value was set at 1 and 20 respectively. The tumor stage (P = 0.022) and tumor site (P = 0.004) were significantly correlated with the PD-L1 expression (CPS > 1). Non-diabetic patients (P = 0.046) were corelated to positive PDL1 expression (CPS > 20). When evaluating PD-L1 expression in 40 laryngeal squamous cell carcinomas (LSC), the nodal stage was found to be significantly associated with high expression of PD-L1 (CPS > 20) (P = 0.042). As for 36 patients with hypopharyngeal squamous cell carcinomas (HPSC), the positive PD-L1 expression (CPS > 1) were typically younger (P = 0.030) and patients without type II diabetes (P = 0.040). We evaluated all possible clinical prognostic factors in the univariate Cox model, and there was no significant correlation between clinical characteristics and survival. The results of our findings may help to understand the association between the PDL1 expression and clinicopathological characteristics, and it showed no significant correlation between the expression of PD-L1 and OS in HNSCC.
引用
收藏
页数:7
相关论文
共 64 条
[51]   Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma [J].
Rasmussen, Jacob H. ;
Lelkaitis, Giedrius ;
Hakansson, Katrin ;
Vogelius, Ivan R. ;
Johannesen, Helle H. ;
Fischer, Barbara M. ;
Bentzen, Soren M. ;
Specht, Lena ;
Kristensen, Claus A. ;
von Buchwald, Christian ;
Wessel, Irene ;
Friborg, Jeppe .
BRITISH JOURNAL OF CANCER, 2019, 120 (10) :1003-1006
[52]   PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma [J].
Roper, Edward ;
Lum, Trina ;
Palme, Carsten E. ;
Ashford, Bruce ;
Ch'ng, Sydney ;
Ranson, Marie ;
Boyer, Michael ;
Clark, Jonathan ;
Gupta, Ruta .
PATHOLOGY, 2017, 49 (05) :499-505
[53]   PD-L1 Expression Correlates With Young Age and CD8+TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma [J].
Saglam, Ozlen ;
Zhou, Junmin ;
Wang, Xuefeng ;
Conejo-Garcia, Jose R. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (05) :428-435
[54]   PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas [J].
Sanchez-Canteli, Mario ;
Granda-Diaz, Rocio ;
del Rio-Ibisate, Nagore ;
Allonca, Eva ;
Lopez-Alvarez, Fernando ;
Agorreta, Jackeline ;
Garmendia, Irati ;
Montuenga, Luis M. ;
Garcia-Pedrero, Juana M. ;
Rodrigo, Juan P. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (10) :2089-2100
[55]  
Shan T, 2019, INT J CLIN EXP PATHO, V12, P1764
[56]  
Sun X., 2021, FRONT ONCOL, V11
[57]   PD-1/PD-L1 inhibitors [J].
Sunshine, Joel ;
Taube, Janis M. .
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 :32-38
[58]   PD-1 blockade induces responses by inhibiting adaptive immune resistance [J].
Tumeh, Paul C. ;
Harview, Christina L. ;
Yearley, Jennifer H. ;
Shintaku, I. Peter ;
Taylor, Emma J. M. ;
Robert, Lidia ;
Chmielowski, Bartosz ;
Spasic, Marko ;
Henry, Gina ;
Ciobanu, Voicu ;
West, Alisha N. ;
Carmona, Manuel ;
Kivork, Christine ;
Seja, Elizabeth ;
Cherry, Grace ;
Gutierrez, Antonio J. ;
Grogan, Tristan R. ;
Mateus, Christine ;
Tomasic, Gorana ;
Glaspy, John A. ;
Emerson, Ryan O. ;
Robins, Harlan ;
Pierce, Robert H. ;
Elashoff, David A. ;
Robert, Caroline ;
Ribas, Antoni .
NATURE, 2014, 515 (7528) :568-+
[59]   B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma [J].
Ukpo O.C. ;
Thorstad W.L. ;
Lewis Jr. J.S. .
Head and Neck Pathology, 2013, 7 (2) :113-121
[60]   Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis [J].
Weng, Yi Ming ;
Peng, Min ;
Hu, Meng Xue ;
Yao, Yi ;
Song, Qi Bin .
ONCOTARGETS AND THERAPY, 2018, 11 :7529-7542